Antiphospholipid antibodies, eicosanoids and expression of endothelial cyclooxygenase-2

Lupus

Volumn 5, Issue 5, 1996, Pages 494-497

  Carreras, L O ^a   Martinuzzo, M E ^a   Maclouf, J ^b  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

^b HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Antiphospholipid antibodies; Cyclooxygenase 2; Eicosanoids; Endothelial cells; Platelet activation

Indexed keywords

ICOSANOID; PHOSPHOLIPID ANTIBODY; PROSTAGLANDIN SYNTHASE;

ANTIPHOSPHOLIPID SYNDROME; CONFERENCE PAPER; PRIORITY JOURNAL;

EID: 0029852860     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/096120339600500533     Document Type: Conference Paper

References (46)

1. Triplett DA. Antiphospholipid antibodies and thrombosis. A consequence, coincidence, or cause?. Arch Pathol Lab Med 1993; 117:78-88.
2. Alarcon-Segovia D. Clinical manifestations of the antiphospholipid syndrome. J Rheumatol 1992; 19:1778-1781.
3. Vermylen J, Amout J. Is the antiphospholipid syndrome caused by antibodies directed against physiologically relevant phospholipid-protein complexes?. J Lab Clin Med 1992; 120:10-12.
4. 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87:4120-4124.
5. Bevers EM et al. Lupus anticoagulant IgGs (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemostas 1991; 66:629-652.
6. Roubey RAS. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other 'antiphospholipid antibodies'. Blood 1994; 84:2854-2867.
7. 2 glycoprotein I structure altered to interact with an oxygen modified solid phase surface. J Exp Med 1994; 179:457-462.
8. 2 glycoprotein I reactivity to monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome. Arthritis Rheum 1994; 37:1453-1461.
9. 2-glycoprotein 1 as an antigen. J Immunol Methods 1991; 143:223-229.
10. 2 Glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med 1992; 93:181-186.
11. 2 Glycoprotein I antibodies: detection and association with thrombosis. Br J Haematol 1995; 89:397-402.
12. Arvieux J et al. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. Thromb Haemostas 1995; 74:1120-1125.
13. Moncada S, Vane JR. Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis. Br Med Bull 1978; 34:129-135.
14. Carreras LO et al. Recurrent arterial thrombosis, repeated intrauterine death and 'lupus' anticoagulant. Detection of immunoglobulin interfering with prostacyclin formation. Lancet 1981; 1:244-246.
15. Carreras LO, Vermylen JG. 'Lupus' anticoagulant and thrombosis. Possible role of inhibition of prostacyclin formation. Thromb Haemostas 1982; 48:38-40.
16. Elias M, Eldor A. Thromboembolism in patients with the 'lupus' type circulating anticoagulant. Arch Intern Med 1984; 144:510-515.
17. Schorer AE, Wickham NWR, Watson KV. Lupus anticoagulant induces a selective defect in thrombin-mediated endothelial prostacyclin release and platelet aggregation. Br J Haematol 1989; 71:399-407.
18. Watson KV, Schorer AE. Lupus anticoagulant inhibition of in vitro prostacyclin release is associated with a thrombosis-prone subset of patients. Am J Med 1991; 90:47-53.
19. Lindsay NJ et al. Inhibition of prostacyclin release by endothelial binding anticardiolipin antibodies in thrombosis-prone patients with systemic lupus erythematosus and antiphospholipid syndrome. Br J Haematol 1994; 33:20-26.
20. Cariou R et al. Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells. Inhibition of thrombomodulin-dependent protein C activation. Thromb Haemostas 1988; 60:54-58.
21. Petraiuolo W, Bovill E, Hoak J. The lupus anticoagulant stimulates the release of prostacyclin from human endothelial cells. Thromb Res 1988; 50:847-855.
22. Carreras LO, Maclouf J. The lupus anticoagulant and eicosanoids. Prostaglandins Leukotrienes and Essential Fatty Acids 1993; 49:483-488.
23. Lellouche F et al. Imbalance of thromboxane/prostacyclin biosynthesis in patients with lupus anticoagulant. Blood 1991; 78:2894-2899.
24. Lellouche F, Falcón C, Carreras L, Maclouf J. Selective inhibition of platelet-derived thromboxane A2 in patients with lupus anticoagulant using low doses aspirin as assessed by enzyme immunoassay. In: Samuelsson B, Ramwell PW, Paoletti R, Folco G, Graastrom E (eds) Advances in Prostaglandins, Thromboxane and Leukotrienes Research, Vol. 21. Raven Press: New York, 1990, 611-614.
25. Kaaja R, Julkunen H, Viinikka L, Ylikorkala O. Production of prostacyclin and thromboxane in lupus pregnancies: Effect of small dose of aspirin. Obstet Gynecol 1993; 81:327-331.
26. Arfors L, Vestergvist O, Johnsson H, Grien K. Increased thromboxane formation in patients with antiphospholipid syndrome. Eur J Clin Invest 1990; 20:607-612.
27. Violi F et al. Thromboxane biosynthesis in patients with systemic lupus erythematosus. Thromb Haemostas 1993; 69:541 (abstract).
28. Schinco PC et al. Lupus anticoagulant: Interference with in vivo prostaglandin production and with platelet sensitivity to prostacyclin. Scand J Rheumatol 1992; 21:124-128.
29. Hasselaar P, Derksen RHWM, Blokzijil L, de Groot PG. Thrombosis associated with antiphospholipid antibodies cannot be explained by effects on endothelial and platelet prostanoid synthesis. Thromb Haemostas 1988; 59:80-85.
30. Lin YL, Wang CT. Activation of human platelets by the rabbit anticardiolipin antibodies. Blood 1992; 80:3135-3143.
31. Martinuzzo ME, Maclouf J, Carreras LO, Lévy Toledano S. Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation. Thromb Haemostas 1993; 70:667-671.
32. Peaceman AM, Rehnberg KA. The effect of immunoglobulin G fractions from patients with lupus anticoagulant on placental prostacyclin and thromboxane production. Am J Obstet Gynecol 1993; 169:1403-1406.
33. Peaceman AM, Rehnberg KA. The effect of aspirin and indomethacin on prostacyclin and thromboxane production by placental tissue incubated with immunoglobulin G fractions from patients with lupus anticoagulant Am J Obstet Gynecol 1995; 173:1391-1396.
34. Shoenfeld Y, Blank M. Effect of long-acting thromboxane receptor antagonist (BMS 180,291) on experimental antiphospholipid syndrome. Lupus 1994; 3:397-400.
35. Habib A et al. Increased expression of inducible cyclooxygenase-2 in human endothelial cells by antiphospholipid antibodies. Thromb Haemostas 1995; 74:770-777.
36. Habib A et al. Demonstration of an inducible cyclooxygenase in human endothelial cells using antibodies raised against the C-terminal region of the cyclooxygenase-2. J Biol Chem 1993; 268:23448-23454.
37. Kujubu DA et al. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991; 266:12866-12872.
38. Moatter T, Gerritsen ME. Fibroblast growth factor upregulates PGG/H synthase in rabbit microvascular endothelial cells by a glucocorticoid-independent mechanism. J Cell Physiol 1992; 151:571-578.
39. 2 activity. J Lab Clin Med 1992; 120:67-77.
40. Ballou LR et al. Interleukin-1-mediated PGE2 production and sphingomyelin metabolism. Evidence for the regulation of cyclooxygenase gene expression by sphingosine and ceramide. J Biol Chem 1992; 267:20044-20050.
41. Murakami M, Matsumoto R, Austen KF, Arm JP. Prostaglandin endoperoxide synthase-1 and -2 couple to different transmembrane stimuli to generate prostaglandin D2 in mouse bone marrow-derived mast cells. J Biol Chem 1994; 269:22269-22275.
42. Morita I et al. Different intracellular locations for prostaglandin endoperoxide synthases-1 and -2. J Biol Chem 1995; 270:10902-10908.
43. De Witt DL, Smith WL. Yes, but do they still get headaches?. Cell 1995; 83:345-348.
44. Tsai AL, Sanduja R, Wu K. Evidence for two pools of prostaglandin H synthase in human endothelial cells. In: Samuelsson B, Ramwell PW, Paoletti R, Folco G, Granstrom E (eds) Advances in Prostaglandins, Thromboxane and Leukotrienes Research, Vol. 21. Raven Press: New York, 1990, pp 141-144.
45. 2 Glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: differences with lupus anticoagulants. Blood 1993; 81:1255-1262.
46. 2 Glycoprotein I. Thromb Haemostas 1993; 70:336-344.